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Background: The aim of study was to compare different coronary stents used during
primary percutaneous coronary intervention (PCI) in female patient with acute
myocardial infarction (AMI) and diabetes mellitus (DM).
Methods: We selected 1799 consecutive AMI female patients (68.910.2) with DM
undergoing primary PCI and divided them into 5 groups based on the types of drug eluting
stents implanted. Sirolimus-eluting stent (SES), Paclitaxel-eluting stent (PES), Ever-
olimus-eluting stent (EES), Biolimus-eluting stent (BES), Zotarolimus-eluting stent
(ZES). Study end point was 12-monthmajor adverse cardiac events (MACE), a composite
of death, fatal and nonfatal myocardial infarction and target vessel revascularization.
Results:Mean Hemoglobin A1c level of SES, PES, EES, BES, ZES was 7.7  1.1%,
7.8 1.3%, 7.8  1.1%, 7.6  1.2%, and 7.7  1.2% respectively (p¼0.195). 928
patients (51.6%) patients prescribed oral hypoglycemic agents (OHA) and 871 pa-
tients prescribed OHA and insulin both.Ejection fraction, systolic blood pressure were
no signiﬁcant difference in ﬁve groups. The incidence of 12-month MACE in SES,
PES, EES, BES, ZES was 8.3%, 8.9%, 4.2%, 4.5%, and 5.2%, respectively (p¼0.02).
Kaplan Meier analysis show signiﬁcant difference between SES and BES (p¼0.046),
SES and EES (p¼0.025), PES and BES (p¼0.021), PES and ZES (p¼0.039), PES and
EES (p¼0.011). Independent predictors of one-year MACE were family history (OR
17.06, 95% CI 8.412-34.61, p< 0.001), serum glucose level(OR 0.304, 95% CI 0.140-
0.661, p¼0.024), serum creatine level (OR 3.933, 95% CI 1.194-12.96, p¼0.024).
Conclusions: In female patient with AMI and DM, EES and BES would be better
therapeutic option than SES and PES for one-year follow up and this result warranted
further long-term follow-up.
TCT-54
Additive Prognostic Value Of The Global Registry Of Acute Coronary Events
Score Over Other Risk Scores For In-Hospital Outcome Prediction In Patients
Presenting With ST-Elevation Myocardial Infarction Treated With Primary
Percutaneous Coronary Intervention
Lorenzo Azzalini1, Razi Khan1, Malek Al-Hawwas1, Raja Hatem1, Annik Fortier1,
Philippe L. L’Allier1, Hung Q. Ly1
1Montreal Heart Institute, Montreal, QC, Canada
Background: Risk stratiﬁcation is of utmost importance in patients with ST-elevation
myocardial infarction (STEMI) treated with primary percutaneous coronary inter-
vention (pPCI). We aimed to compare different risk scores to evaluate their predictive
power towards in-hospital outcomes.
Methods: In 241 consecutive STEMI patients referred for pPCI, the GRACE, TIMI,
Zwolle, CADILLAC, PAMI, SYNTAX, and residual SYNTAX (rSS) scores were
calculated. The endpoints of this study were in-hospital death, major adverse cardiac
events (MACE: death, recurrent myocardial infarction and urgent revascularization)
and major adverse events (MAE: MACE, heart failure, stroke, acute kidney injury and
major bleeding). The C-statistic was utilized for comparisons.
Results: Mean age was 62.212.6 years, 77.2% were male and 16.2% diabetics. Mean
ejection fraction was 47.89.6%. The culprit lesion was the LAD in 38.6% and 44.4%
had multivessel disease. All scores were signiﬁcantly associated with the 3 outcomes on
univariate analysis, except the rSS (with death,MACEandMAE).As shown in theTable,
the GRACE score showed the highest C-statistic for all endpoints: death (0.8866, 95%
CI: 0.8058 to 0.9674), MACE (0.8168; 95% CI: 0.7078 to 0.9258) and MAE (0.7922,
95% CI: 0.7151 to 0.8693). The GRACE score signiﬁcantly outperformed the other
6 scores for all 3 endpoints (except the Zwolle and CADILLAC risk scores for MAE).Conclusions: In a contemporary population of STEMI patients treated with
pPCI, the GRACE score was the best predictor of in-hospital death, MACE
and MAE.B16 JACC Vol 64/11/Suppl B jTCT-55
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Background: The recent PRAMI trial has shown that in patients with STEMI, im-
mediate preventive PCI to non-culprit lesions reduced the risk of major adverse car-
diovascular events (MACE). We conducted an online survey to assess current
approaches and to determine whether the PRAMI results are being translated into
clinical practice.
Methods: Email invitations to participate in a SurveyMonkey questionnaire were
sent to interventional cardiologists in the United Kingdom (UK), United States of
America (USA), Switzerland and Australia and New Zealand (ANZ).
Results: Of the 288 responses, 146 (50.7%) were from the UK, 59 (20.5%) from
USA, 39 (13.6%) from Switzerland, and 44 (15.2%) from ANZ. The majority of
respondents opted for medical therapy for lesions of 50-70% severity (n¼196, 76.1%)
and staged PCI for lesions of 70-90% severity (n¼203, 76.6%). In patients with >90%
stenosis, 28.2% (n¼77) opted for immediate PCI and 65.6% (n¼179) for staged PCI.
Respondents most frequently opted to perform staged PCI during the index admission
for stenoses of >90% severity (n¼121, 47.8%) and to delay it for 4-6 weeks for other
lesion severities (n¼192, 43.7%). Most respondents were either uncertain that im-
mediate preventive PCI prevents MACE (n¼119, 41.3%) or did not believe that it
does (n¼125, 43.4%).Conclusions: Only a minority of interventional cardiologists are persuaded that pre-
ventive PCI reduces the risk of MACE. Furthermore, most would perform staged
rather than immediate PCI. Further studies are required to conﬁrm or refute the
PRAMI results and to address the optimal timing of PCI to non-culprit lesions.
TCT-56
Correlation Between Residual Platelet Reactivity After Clopidogrel Loading And
Long Term Major Adverse Outcome Among STEMI Patients Undergoing
Delayed Primary Percutaneous Coronary Intervention
Manolis Vavuranakis1, Konstantinos Kalogeras1, NIKOLAOS DAGRES2,
Maria Kariori3, Maria Lavda4, Carmen Moldovan3, Evangelia Bei5,
Dimitrios A. Vrachatis6, Christodoulos Stefanadis7
11st Dept. of Cardiology, Hippokration Hospital, Medical School of Athens, Athens,
Greece, 22nd Department of Cardiology, University of Athens, Attikon Hospital,
athens, Greece, 31st Department of Cardiology, Hippokration Hospital, National and
Kapodistrian University of Athens, Athens, Greece, 41st Department of Cardiology,
Hippokrateion Hospital, athens, Greece, 51st Department of Cardiology, ATHENS,
Greece, 61st Department of Cardiology, Hippokration Hospital, Athens, Greece,
7Athens Medical Center, Athens, Greece
Background: It has been shown that higher Residual Platelet Reactivity RPR
(P2Y12-Reaction-Units,PRU>251.5) after clopidogrel loading is associated with
larger intracoronary thrombus burden, as well as with impaired myocardial perfusionSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
